2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2807

Association of Exposure to Childhood Abuse with Incident Systemic Lupus Erythematosus in a Longitudinal Cohort of Women
Abstract Number: 2808

T-Score As an Indicator of Fracture Risk on Therapy: Evidence from Romosozumab Vs Alendronate Treatment in the Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk Trial
Abstract Number: 2809

Skeletal Benefit/Risk of Long-Term Denosumab Therapy: A Virtual Twin Analysis of Fractures Prevented to Skeletal Safety Events Observed
Abstract Number: 2810

Fracture and Bone Mineral Density Response By Baseline Risk in Patients Treated with Abaloparatide Followed By Alendronate
Abstract Number: 2811

Abaloparatide Effect on Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis Aged 80 Years or Older
Abstract Number: 2812

Evaluation of Cortical Microarchitecture, Bone Stiffness and Bone Remodeling in Patients with Atypical Femoral Fracture
Abstract Number: 2813

Risk of Venous Thromboembolism with Selective Estrogen Receptor Modulators for Postmenopausal Osteoporosis: A Meta-Analysis of Randomized Trials
Abstract Number: 2814

Methotrexate Use and the Risk for Cardiovascular Disease Among Rheumatoid Patients Initiating Biologic Disease-Modifying Anti-Rheumatic Drugs
Abstract Number: 2815

Cardiovascular Safety – Update from up to 6 Years of Treatment with Baricitinib in Rheumatoid Arthritis Clinical Trials
Abstract Number: 2816

Development of a Microrna Panel for Predicting Coronary Atherosclerosis in Rheumatoid Arthritis
Abstract Number: 2817

Cardiovascular Disease Risk with Biologics and Tofacitinib Compared to Conventional Synthetic Dmards in Patients with Rheumatoid Arthritis
Abstract Number: 2818

Galectin-3 As a Marker of Subclinical Atherosclerosis, Arterial Stiffness and Myocardial Performance in Patients with Rheumatoid Arthritis
Abstract Number: 2819

Alcohol Consumption and the Risk of Coronary Heart Disease and Mortality in Patients with Rheumatoid Arthritis
Abstract Number: 2820

Sustained Clinical Remission after Discontinuation of Infliximab with a Raising Dose Strategy in Patients with Rheumatoid Arthritis (RRRR study): A Randomized Controlled Trial
Abstract Number: 2821

Dose Tapering and Discontinuation of Biological Therapy in Rheumatoid Arthritis Patients in Routine Care – 2-Year Outcomes and Predictors

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].